ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $1.22 billion. The enterprise value is $952.33 million.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 100.36 million shares outstanding. The number of shares has increased by 25.91% in one year.
| Current Share Class | 100.36M |
| Shares Outstanding | 100.36M |
| Shares Change (YoY) | +25.91% |
| Shares Change (QoQ) | +3.67% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 87.90% |
| Float | 67.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.13 |
| P/TBV Ratio | 3.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.13, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.13 |
| Quick Ratio | 13.79 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.27% and return on invested capital (ROIC) is -27.74%.
| Return on Equity (ROE) | -41.27% |
| Return on Assets (ROA) | -26.17% |
| Return on Invested Capital (ROIC) | -27.74% |
| Return on Capital Employed (ROCE) | -36.81% |
| Weighted Average Cost of Capital (WACC) | 11.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 104 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.35% in the last 52 weeks. The beta is 1.36, so ORIC's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +56.35% |
| 50-Day Moving Average | 11.36 |
| 200-Day Moving Average | 10.93 |
| Relative Strength Index (RSI) | 50.62 |
| Average Volume (20 Days) | 1,713,414 |
Short Selling Information
The latest short interest is 21.79 million, so 21.72% of the outstanding shares have been sold short.
| Short Interest | 21.79M |
| Short Previous Month | 22.10M |
| Short % of Shares Out | 21.72% |
| Short % of Float | 32.26% |
| Short Ratio (days to cover) | 14.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -143.00M |
| Pretax Income | -129.47M |
| Net Income | -129.47M |
| EBITDA | -141.78M |
| EBIT | -143.00M |
| Earnings Per Share (EPS) | -$1.47 |
Full Income Statement Balance Sheet
The company has $281.49 million in cash and $7.44 million in debt, with a net cash position of $274.05 million or $2.73 per share.
| Cash & Cash Equivalents | 281.49M |
| Total Debt | 7.44M |
| Net Cash | 274.05M |
| Net Cash Per Share | $2.73 |
| Equity (Book Value) | 384.36M |
| Book Value Per Share | 3.90 |
| Working Capital | 268.05M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$110.97 million and capital expenditures -$712,000, giving a free cash flow of -$111.68 million.
| Operating Cash Flow | -110.97M |
| Capital Expenditures | -712,000 |
| Free Cash Flow | -111.68M |
| FCF Per Share | -$1.11 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.91% |
| Shareholder Yield | -25.91% |
| Earnings Yield | -10.56% |
| FCF Yield | -9.11% |
Analyst Forecast
The average price target for ORIC is $20.00, which is 65.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 65.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -23.86% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |